Bluestar Genomics, Inc., an early cancer detection company leading the development and commercialization of next-generation liquid biopsy approaches initially focused on non-invasive detection of high-mortality cancers through a standard blood draw, today announced that its Chief Executive Officer David Mullarkey will participate in the Goldman Sachs fireside chat “The New Guard: Privates Leading The Disruption in Healthcare” on April 7, 2022 at 1:00 p.m., Eastern time.
“It’s an honor to participate in this discussion and I look forward to sharing insights into how the convergence of genomic science and technology is advancing liquid biopsy to become a standard of care in cancer management,” said Mullarkey. “Our first test for the detection of pancreatic cancer, awarded by the FDA with a breakthrough device designation, is just one example of how we can fulfill the promise of early cancer detection from a standard blood draw to transform the management of high-mortality cancers and ultimately help save lives.”
More than 600,000 people died from cancer last year in the United States, according to the American Cancer Society. This is in large part because some difficult-to-find cancers are found too late, when treatments are limited.
For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybersecurity, go to AI-Techpark.com.